Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Defining and Applying Locally Relevant Benchmarks for the Adenoma Detection Rate.

Hilsden RJ, Rose SM, Dube C, Rostom A, Bridges R, McGregor SE, Brenner DR, Heitman SJ.

Am J Gastroenterol. 2019 Aug;114(8):1315-1321. doi: 10.14309/ajg.0000000000000120.

PMID:
30848731
2.

Determinants of changes in physical activity from pre-diagnosis to post-diagnosis in a cohort of prostate cancer survivors.

Stone CR, Courneya KS, McGregor SE, Li H, Friedenreich CM.

Support Care Cancer. 2019 Aug;27(8):2819-2828. doi: 10.1007/s00520-018-4578-2. Epub 2018 Dec 12.

PMID:
30543049
3.

Reply to 'Comment on 'Anthropometric measurements and survival after prostate cancer diagnosis".

Farris MS, Courneya KS, Kopciuk KA, McGregor SE, Friedenreich CM.

Br J Cancer. 2018 Aug;119(4):525-526. doi: 10.1038/s41416-018-0213-8. Epub 2018 Jul 31. No abstract available.

4.

Post-diagnosis alcohol intake and prostate cancer survival: A population-based cohort study.

Farris MS, Courneya KS, Kopciuk KA, McGregor SE, Friedenreich CM.

Int J Cancer. 2018 Jul 15;143(2):253-262. doi: 10.1002/ijc.31307. Epub 2018 Feb 23.

5.

Patterns and predictors of adherence to colorectal cancer screening recommendations in Alberta's Tomorrow Project participants stratified by risk.

Solbak NM, Xu JY, Vena JE, Al Rajabi A, Vaseghi S, Whelan HK, McGregor SE.

BMC Public Health. 2018 Jan 25;18(1):177. doi: 10.1186/s12889-018-5095-4.

6.

The association between recreational physical activity, sedentary time, and colorectal polyps in a population screened for colorectal cancer.

Brenner DR, Shaw E, Yannitsos DH, Warkentin MT, Brockton NT, McGregor SE, Town S, Hilsden RJ.

Cancer Epidemiol. 2018 Apr;53:12-20. doi: 10.1016/j.canep.2017.12.017. Epub 2018 Jan 30.

PMID:
29353151
7.

A quantitative multimodal metabolomic assay for colorectal cancer.

Farshidfar F, Kopciuk KA, Hilsden R, McGregor SE, Mazurak VC, Buie WD, MacLean A, Vogel HJ, Bathe OF.

BMC Cancer. 2018 Jan 4;18(1):26. doi: 10.1186/s12885-017-3923-z.

8.

Anthropometric measurements and survival after a prostate cancer diagnosis.

Farris MS, Courneya KS, Kopciuk KA, McGregor SE, Friedenreich CM.

Br J Cancer. 2018 Feb 20;118(4):607-610. doi: 10.1038/bjc.2017.440. Epub 2017 Dec 12.

9.

Intake of dietary fibre and lifetime non-steroidal anti-inflammatory drug (NSAID) use and the incidence of colorectal polyps in a population screened for colorectal cancer.

Shaw E, Warkentin MT, McGregor SE, Town S, Hilsden RJ, Brenner DR.

J Epidemiol Community Health. 2017 Oct;71(10):961-969. doi: 10.1136/jech-2016-208606. Epub 2017 Aug 28.

10.

Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.

Ten Haaf K, Tammemägi MC, Bondy SJ, van der Aalst CM, Gu S, McGregor SE, Nicholas G, de Koning HJ, Paszat LF.

PLoS Med. 2017 Feb 7;14(2):e1002225. doi: 10.1371/journal.pmed.1002225. eCollection 2017 Feb.

11.

Alberta's Tomorrow Project: adherence to cancer prevention recommendations pertaining to diet, physical activity and body size.

Whelan HK, Xu JY, Vaseghi S, Lo Siou G, McGregor SE, Robson PJ.

Public Health Nutr. 2017 May;20(7):1143-1153. doi: 10.1017/S1368980016003451. Epub 2017 Jan 25.

12.

Identification and prediction of health-related quality of life trajectories after a prostate cancer diagnosis.

Farris MS, Kopciuk KA, Courneya KS, McGregor SE, Wang Q, Friedenreich CM.

Int J Cancer. 2017 Apr 1;140(7):1517-1527. doi: 10.1002/ijc.30586. Epub 2017 Jan 6.

13.

Design, methods and demographics from phase I of Alberta's Tomorrow Project cohort: a prospective cohort profile.

Robson PJ, Solbak NM, Haig TR, Whelan HK, Vena JE, Akawung AK, Rosner WK, Brenner DR, Cook LS, Csizmadi I, Kopciuk KA, McGregor SE, Friedenreich CM.

CMAJ Open. 2016 Sep 29;4(3):E515-E527. eCollection 2016 Jul-Sep.

14.

Defining Benchmarks for Adenoma Detection Rate and Adenomas Per Colonoscopy in Patients Undergoing Colonoscopy Due to a Positive Fecal Immunochemical Test.

Hilsden RJ, Bridges R, Dube C, McGregor SE, Naugler C, Rose SM, Rostom A, Heitman SJ.

Am J Gastroenterol. 2016 Dec;111(12):1743-1749. doi: 10.1038/ajg.2016.449. Epub 2016 Oct 11.

PMID:
27725649
15.

Associations of Postdiagnosis Physical Activity and Change from Prediagnosis Physical Activity with Quality of Life in Prostate Cancer Survivors.

Farris MS, Kopciuk KA, Courneya KS, McGregor SE, Wang Q, Friedenreich CM.

Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):179-187. doi: 10.1158/1055-9965.EPI-16-0465. Epub 2016 Sep 27.

16.

A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.

Farshidfar F, Weljie AM, Kopciuk KA, Hilsden R, McGregor SE, Buie WD, MacLean A, Vogel HJ, Bathe OF.

Br J Cancer. 2016 Sep 27;115(7):848-57. doi: 10.1038/bjc.2016.243. Epub 2016 Aug 25.

17.

Physical Activity and Survival After Prostate Cancer.

Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA, McGregor SE, Courneya KS.

Eur Urol. 2016 Oct;70(4):576-585. doi: 10.1016/j.eururo.2015.12.032. Epub 2016 Jan 7.

18.

Evaluation of a clinical risk index for advanced colorectal neoplasia among a North American population of screening age.

Ruco A, Stock D, Hilsden RJ, McGregor SE, Paszat LF, Saskin R, Rabeneck L.

BMC Gastroenterol. 2015 Nov 19;15:162. doi: 10.1186/s12876-015-0395-y.

19.

The association of colonoscopy quality indicators with the detection of screen-relevant lesions, adverse events, and postcolonoscopy cancers in an asymptomatic Canadian colorectal cancer screening population.

Hilsden RJ, Dube C, Heitman SJ, Bridges R, McGregor SE, Rostom A.

Gastrointest Endosc. 2015 Nov;82(5):887-94. doi: 10.1016/j.gie.2015.03.1914. Epub 2015 May 5.

PMID:
25952092
20.

Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study.

Myers RP, Crotty P, Town S, English J, Fonseca K, Tellier R, Swain MG, McGregor SE, Heitman SJ, Hilsden RJ.

CMAJ Open. 2015 Jan 13;3(1):E62-7. doi: 10.9778/cmajo.20140024. eCollection 2015 Jan-Mar.

21.

Evaluation of a risk index for advanced proximal neoplasia of the colon.

Ruco A, Stock D, Hilsden RJ, McGregor SE, Paszat LF, Saskin R, Rabeneck L.

Gastrointest Endosc. 2015;81(6):1427-32. doi: 10.1016/j.gie.2014.12.028. Epub 2015 Mar 11.

PMID:
25771065
22.

Advanced proximal neoplasia of the colon in average-risk adults.

Rabeneck L, Paszat LF, Hilsden RJ, McGregor SE, Hsieh E, M Tinmouth J, Baxter NN, Saskin R, Ruco A, Stock D.

Gastrointest Endosc. 2014 Oct;80(4):660-667. doi: 10.1016/j.gie.2014.02.001. Epub 2014 Mar 27.

PMID:
24679656
23.

ColonCancerCheck primary care invitation pilot project: patient perceptions.

Tinmouth J, Ritvo P, McGregor SE, Patel J, Guglietti C, Levitt CA, Paszat LF, Rabeneck L.

Can Fam Physician. 2013 Dec;59(12):e541-9.

24.

Case-control study of lifetime alcohol intake and prostate cancer risk.

McGregor SE, Courneya KS, Kopciuk KA, Tosevski C, Friedenreich CM.

Cancer Causes Control. 2013 Mar;24(3):451-61. doi: 10.1007/s10552-012-0131-7. Epub 2012 Dec 28.

PMID:
23271409
25.

ColonCancerCheck Primary Care Invitation Pilot project: family physician perceptions.

Tinmouth J, Ritvo P, McGregor SE, Guglietti C, Green J, Claus D, Levitt C, Paszat LF, Rabeneck L.

Can Fam Physician. 2012 Oct;58(10):e570-7.

26.

Development and implementation of a comprehensive quality assurance program at a community endoscopy facility.

Hilsden RJ, Rostom A, Dubé C, Pontifex D, McGregor SE, Bridges RJ.

Can J Gastroenterol. 2011 Oct;25(10):547-54.

27.

Effective interventions to facilitate the uptake of breast, cervical and colorectal cancer screening: an implementation guideline.

Brouwers MC, De Vito C, Bahirathan L, Carol A, Carroll JC, Cotterchio M, Dobbins M, Lent B, Levitt C, Lewis N, McGregor SE, Paszat L, Rand C, Wathen N.

Implement Sci. 2011 Sep 29;6:112. doi: 10.1186/1748-5908-6-112. Review.

28.

What implementation interventions increase cancer screening rates? a systematic review.

Brouwers MC, De Vito C, Bahirathan L, Carol A, Carroll JC, Cotterchio M, Dobbins M, Lent B, Levitt C, Lewis N, McGregor SE, Paszat L, Rand C, Wathen N.

Implement Sci. 2011 Sep 29;6:111. doi: 10.1186/1748-5908-6-111. Review.

29.

Reactions to a targeted intervention to increase fecal occult blood testing among average-risk adults waiting for screening colonoscopy.

McGregor SE, Ritvo P, Tinmouth J, Kornblum A, Myers R, Hilsden RJ, Paszat LF, Rabeneck L.

Can J Gastroenterol. 2011 May;25(5):248-52.

30.

Exploring statistical approaches to diminish subjectivity of cluster analysis to derive dietary patterns: The Tomorrow Project.

Lo Siou G, Yasui Y, Csizmadi I, McGregor SE, Robson PJ.

Am J Epidemiol. 2011 Apr 15;173(8):956-67. doi: 10.1093/aje/kwq458. Epub 2011 Mar 18.

PMID:
21421742
31.

A qualitative evaluation of strategies to increase colorectal cancer screening uptake.

Tinmouth J, Ritvo P, McGregor SE, Claus D, Pasut G, Myers RE, Guglietti C, Paszat LF, Hilsden RJ, Rabeneck L.

Can Fam Physician. 2011 Jan;57(1):e7-15.

32.

Cohorts and consortia conference: a summary report (Banff, Canada, June 17-19, 2009).

Boffetta P, Colditz GA, Potter JD, Kolonel L, Robson PJ, Malekzadeh R, Seminara D, Goode EL, Yoo KY, Demers P, Gallagher R, Prentice R, Yasui Y, O'Doherty K, Petersen GM, Ulrich CM, Csizmadi I, Amankwah EK, Brockton NT, Kopciuk K, McGregor SE, Kelemen LE.

Cancer Causes Control. 2011 Mar;22(3):463-8. doi: 10.1007/s10552-010-9717-0. Epub 2011 Jan 4.

PMID:
21203821
33.

Measuring Preferences for Colorectal Cancer Screening: What are the Implications for Moving Forward?

Marshall D, McGregor SE, Currie G.

Patient. 2010 Jun 1;3(2):79-89. doi: 10.2165/11532250-000000000-00000.

PMID:
22273359
34.

Optimization of preventive health care facility locations.

Gu W, Wang X, McGregor SE.

Int J Health Geogr. 2010 Mar 18;9:17. doi: 10.1186/1476-072X-9-17. Review.

35.

Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.

Heitman SJ, Au F, Manns BJ, McGregor SE, Hilsden RJ.

Clin Gastroenterol Hepatol. 2008 Aug;6(8):912-917.e1. doi: 10.1016/j.cgh.2008.03.006. Epub 2008 Jun 5.

PMID:
18534918
36.

Perception versus reality: overcoming barriers to colorectal cancer screening.

Bryant H, McGregor SE.

Can Fam Physician. 2008 Apr;54(4):495-7. No abstract available.

37.

Validation of self-reported history of colorectal cancer screening.

Khoja S, McGregor SE, Hilsden RJ.

Can Fam Physician. 2007 Jul;53(7):1192-7.

38.

Low uptake of colorectal cancer screening 3 yr after release of national recommendations for screening.

McGregor SE, Hilsden RJ, Li FX, Bryant HE, Murray A.

Am J Gastroenterol. 2007 Aug;102(8):1727-35. Epub 2007 Apr 16.

PMID:
17437502
39.

Predictors of colorectal cancer screening: a comparison of men and women.

McGregor SE, Bryant HE.

Can J Gastroenterol. 2005 Jun;19(6):343-9.

PMID:
15997267
40.

Colorectal cancer screening: practices and opinions of primary care physicians.

McGregor SE, Hilsden RJ, Murray A, Bryant HE.

Prev Med. 2004 Aug;39(2):279-85.

PMID:
15226036
41.

Case-control study of anthropometric measures and prostate cancer risk.

Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ, Elliott FG.

Int J Cancer. 2004 Jun 10;110(2):278-83.

42.

Case-control study of lifetime total physical activity and prostate cancer risk.

Friedenreich CM, McGregor SE, Courneya KS, Angyalfi SJ, Elliott FG.

Am J Epidemiol. 2004 Apr 15;159(8):740-9.

PMID:
15051583
43.

Prevalence of PSA testing and effect of clinical indications on patterns of PSA testing in a population-based sample of Alberta men.

McGregor SE, Bryant HE, Brant RF, Corbett PJ.

Chronic Dis Can. 2002 Summer;23(3):111-9.

PMID:
12443567
44.

The natural history of CIN I lesions.

Duggan MA, McGregor SE, Stuart GC, Morris S, Chang-Poon V, Schepansky A, Honore L.

Eur J Gynaecol Oncol. 1998;19(4):338-44.

PMID:
9744721
45.

Predictors of co-incidental CIN II/III amongst a cohort of women with CIN I detected by a screening Pap test.

Duggan MA, McGregor SE, Stuart GC, Morris S, Chang-Poon V, Schepansky A, Honore L.

Eur J Gynaecol Oncol. 1998;19(3):209-14.

PMID:
9641215
46.

Review of the screening history of Alberta women with invasive cervical cancer.

Stuart GC, McGregor SE, Duggan MA, Nation JG.

CMAJ. 1997 Sep 1;157(5):513-9.

47.

The HPV determinants of CIN I.

Duggan MA, McGregor SE, Stuart GC, Morris S, Chang-Poon V, Schepansky A, Honore L.

Eur J Gynaecol Oncol. 1997;18(2):117-23.

PMID:
9105860
48.

Involving family physicians in education programs for cervical cancer screening.

McGregor SE, Leinweber CE.

Ann N Y Acad Sci. 1995 Sep 30;768:289-91. No abstract available.

PMID:
8526369
49.

The human papillomavirus status of invasive cervical adenocarcinoma: a clinicopathological and outcome analysis.

Duggan MA, McGregor SE, Benoit JL, Inoue M, Nation JG, Stuart GC.

Hum Pathol. 1995 Mar;26(3):319-25.

PMID:
7890285
50.

Adenocarcinoma in situ of the endocervix: human papillomavirus determination by dot blot hybridization and polymerase chain reaction amplification.

Duggan MA, Benoit JL, McGregor SE, Inoue M, Nation JG, Stuart GC.

Int J Gynecol Pathol. 1994 Apr;13(2):143-9.

PMID:
8005736

Supplemental Content

Loading ...
Support Center